[{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Enasidenib","moa":"||IDH","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Theravia","sponsor":"Norgine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cytotoxic Drug","year":"2025","type":"Acquisition","leadProduct":"Hydroxyurea","moa":"||DNA synthesis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Theravia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Theravia \/ Norgine","highestDevelopmentStatusID":"15","companyTruncated":"Theravia \/ Norgine"},{"orgOrder":0,"company":"Global Health Uganda","sponsor":"Columbia University | The University of Pittsburgh School of Medicine | Gabrail Cancer Center Research | Mulago Hospital, Uganda | Makerere University | Gansu Provincial Maternal and Child Health Care Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Hydroxyurea","moa":"||Ribonucleoside-diphosphate reductase RR1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Global Health Uganda","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Global Health Uganda \/ Columbia University | The University of Pittsburgh School of Medicine | Gabrail Cancer Center Research | Mulago Hospital, Uganda | Makerere University | Gansu Provincial Maternal and Child Health Care Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Global Health Uganda \/ Columbia University | The University of Pittsburgh School of Medicine | Gabrail Cancer Center Research | Mulago Hospital, Uganda | Makerere University | Gansu Provincial Maternal and Child Health Care Hospital"},{"orgOrder":0,"company":"Theravia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hydroxyurea","moa":"||Ribonucleoside-diphosphate reductase RR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Theravia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Theravia \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theravia \/ Inapplicable"},{"orgOrder":0,"company":"Theravia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hydroxyurea","moa":"||Ribonucleoside-diphosphate reductase RR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Theravia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Theravia \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theravia \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Hydroxyurea","moa":"||Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Brown University","sponsor":"National Heart, Lung, and Blood Institute | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Hydroxyurea","moa":"||Ribonucleoside-diphosphate reductase RR1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Brown University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brown University \/ National Heart, Lung, and Blood Institute | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Brown University \/ National Heart, Lung, and Blood Institute | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Uma Borate","sponsor":"Kura Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Bone Marrow Aspiration","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Uma Borate","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uma Borate \/ Kura Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Uma Borate \/ Kura Oncology"},{"orgOrder":0,"company":"Theravia","sponsor":"Simbec-Orion | Oncodesign | PhinC Development","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hydroxyurea","moa":"||Ribonucleoside-diphosphate reductase RR1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Theravia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Theravia \/ Simbec-Orion | Oncodesign | PhinC Development","highestDevelopmentStatusID":"6","companyTruncated":"Theravia \/ Simbec-Orion | Oncodesign | PhinC Development"}]

Find Clinical Drug Pipeline Developments & Deals for Urea, hydroxy-

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          02

                          Uma Borate

                          Country arrow
                          EPSC
                          Not Confirmed

                          Uma Borate

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 16, 2025

                          Lead Product(s) : Bone Marrow Aspiration,Cytarabine,Hydroxyurea,Ziftomenib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Kura Oncology

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Through the acquisition, Norgine will have six core products in its rare disease portfolio, which includes Siklos (hydroxyurea) is being indicated for the treatment of sickle cell anemia.

                          Product Name : Siklos

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Undisclosed

                          April 15, 2025

                          Lead Product(s) : Hydroxyurea,Inapplicable

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Sponsor : Norgine

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 29, 2024

                          Lead Product(s) : Hydroxyurea,Inapplicable

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          May 10, 2023

                          Lead Product(s) : Hydroxyurea,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 22, 2022

                          Lead Product(s) : Hydroxyurea,Inapplicable

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Brown University

                          Country arrow
                          EPSC
                          Not Confirmed

                          Brown University

                          Country arrow
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Hydroxyurea,Inapplicable

                          Therapeutic Area : Genetic Disease

                          Study Phase : Phase III

                          Sponsor : National Heart, Lung, and Blood Institute | Novartis Pharmaceuticals Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          March 18, 2022

                          Lead Product(s) : Hydroxyurea,Inapplicable

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : National Heart, Lung, and Blood Institute | Novartis Pharmaceuticals Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 27, 2021

                          Lead Product(s) : Hydroxyurea,Inapplicable

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Simbec-Orion | Oncodesign | PhinC Development

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Global Health Uganda

                          Country arrow
                          EPSC
                          Not Confirmed

                          Global Health Uganda

                          Country arrow
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Hydroxyurea,Inapplicable

                          Therapeutic Area : Genetic Disease

                          Study Phase : Phase III

                          Sponsor : Columbia University | The University of Pittsburgh School of Medicine | Gabrail Cancer Center Research | Mulago Hospital, Uganda | Makerere University | Gansu Provincial Maternal and Child Health Care Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          February 11, 2021

                          Lead Product(s) : Hydroxyurea,Inapplicable

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : Columbia University | The University of Pittsburgh School of Medicine | Gabrail Cancer Center Research | Mulago Hospital, Uganda | Makerere University | Gansu Provincial Maternal and Child Health Care Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Phase 3 IDHENTIFY study evaluating IDHIFA®(enasidenib) plus best supportive care vs conventional care regimens, which include azacitidine plus BSC, low-dose cytarabine plus BSC or intermediate-dose cytarabine plus BSC, did not meet the primary endpoint.

                          Product Name : Idhifa

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 25, 2020

                          Lead Product(s) : Enasidenib,Hydroxyurea

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank